P1–3 received G-CSF treatment before commencing with empagliflozin; however, it did not prevent neutropenia-related symptoms, and absolute neutrophil count (ANC) often remained within the neutropenic range (Figure 3). This evidence concerns the gene CSF3 and neutropenia.